Investigators say that the lead drug--ADS-5102, reformulated in a way designed to reduce the severity of side effects that plague patients--demonstrated a statistically significant improvement in levodopa-induced dyskinesia when compared with a placebo after 8 weeks of therapy.
With rates of oral cancer linked to HPV infection on the rise, a group of investigators has pinned down a new biomarker that can be used to identify high-risk patients.
In its 9 years in operation, PatientsLikeMe has recruited more than 200,000 members, culling data on symptoms, treatments and responses from disease sufferers around the world. Now, in its first deal with a CRO, the company has paired up with inVentiv Health to help recruit for clinical trials.
Eli Lilly is stepping in to take control of an experimental diabetes drug from Canada's Transition Therapeutics, paying $7 million upfront and promising up to $240 million in milestones. The drug--TT-401--is headed into Phase II. Transition will pay Lilly $14 million in installments to complete the Phase II trial.
Patient-recruitment specialist Synexus has won a place in Pfizer's stable of preferred providers, giving the company advance information about future clinical trials and a leg up on other outsourcers.
In yet another indication of the yawning gap between what drug developers know about Alzheimer's and how it could be treated, Eli Lilly today decided to scrap its Phase II study for a BACE inhibitor after gathering abnormal liver tests from patients.
GlaxoSmithKline has stopped development of an experimental drug for multiple sclerosis after a preclinical study turned out to contain "misrepresentations" in data from its R&D labs in China.
Efficacy results for an experimental rheumatoid arthritis drug in development by Eli Lilly and Incyte held up well as patients in a Phase IIb trial were tracked over the course of a full year.
Once again, Amgen's R&D chief Sean Harper has Roger Perlmutter to thank for a positive late-stage outcome on one of the Big Biotech's top cancer prospects.
The lung cancer vaccine race has brought together an unusual mix of players. Merck KGaA was in a good position, but its vaccine disappointed in Phase III, while GlaxoSmithKline could report data on its candidate this year. Then there is the Cuba-Argentina joint venture.